The Globe and Mail reports in its Wednesday edition that RBC Dominion Securities analyst Douglas Miehm has started coverage on Well Health Technologies with an "outperform" recommendation. The Globe's David Leeder writes in the Eye On Equities column that Mr. Miehm set a share target of $5.50. Analysts on average target the shares at $7.44. Mr. Miehm says in a note: "We see Well Health Technologies as a complex, largely misunderstood company and believe the market under-appreciates the long-term value-creating opportunity in transforming Canadian primary/Dx care, as underscored by our strong forecasted ROIC and IRR metrics for recent acquisitions. In the U.S., Well Health should benefit from high organic growth (20 per cent plus) businesses, Circle and Wisp, and high-margin CRH. As investors start to grasp the potential opportunity available to Well Health, we believe the shares will strengthen and outperform peers." The Globe reported on Nov. 12, 2022, and Nov. 16, 2023, that Desjardins had reiterated its "hold" call for Well Health when it was worth $3.12 and $3.79. The Globe reported on Jan. 23, 2024, that CIBC analyst Scott Fletcher had cut Well Health to "neutral" from "outperformer." It was then worth $3.67.